Birth defects and neonatal morbidity caused by teratogen exposure after the embryonic period

Angela E. Scheuerle, Arthur S. Aylsworth

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Pharmaceutical pregnancy exposure registries seek to evaluate temporal associations between drug exposures and adverse outcomes, particularly congenital anomalies. These registries record observed associations that may or may not be causally-related to the exposure. Most major congenital malformations (i.e., structural birth defects) result from abnormal development during embryogenesis. A standardized catalog of defects of concern (colloquially the “BPA Codes”) is used both in public health surveillance programs and pregnancy exposure registries. There are, however, some anomalies that cause significant morbidity and mortality for which isolated second or third trimester exposures may be pathogenically significant. There currently exists no standardized list of defects for which exposure limited to the fetal period may be problematic. Methods: The six-digit-code list was used to determine anomalies that might result from medication exposures limited to the fetal period. Results: Defects with documented first trimester pathogenesis (e.g., anencephaly, heterotaxy) were eliminated from consideration, as were chromosomal and single gene disorders (e.g., trisomy 21, achondroplasia). The remaining defects include the following: (1) those that are known to or could reasonably originate or manifest after the embryonic period (e.g., porencephaly, cataracts); (2) those for which pathogenesis is unclear or variable enough that exposure at any gestational age might be considered relevant (e.g., club foot, microcephaly); and (3) those that include some component of abnormal growth (e.g., hemihyperplasia). “Unspecified” defects (e.g., “abnormality of the leg”) were included by default because there is insufficient information to assume first trimester embryogenesis. Conclusion: The final result is a list of major and minor anomalies in 11 organ system categories that may be caused by teratogen exposure during the fetal period. Birth Defects Research (Part A) 106:935–939, 2016.

Original languageEnglish (US)
Pages (from-to)935-939
Number of pages5
JournalBirth Defects Research Part A - Clinical and Molecular Teratology
Volume106
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Teratogens
Registries
First Pregnancy Trimester
Morbidity
Embryonic Development
Public Health Surveillance
Achondroplasia
Anencephaly
Pregnancy
Microcephaly
Third Pregnancy Trimester
Second Pregnancy Trimester
Down Syndrome
Pharmaceutical Preparations
Cataract
Gestational Age
Foot
Leg
Mortality
Growth

Keywords

  • congenital anomaly
  • fetal period
  • pharmaceutical pregnancy registry
  • pregnancy
  • pregnancy exposure registry
  • second trimester
  • teratogen
  • third trimester

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Embryology
  • Developmental Biology

Cite this

Birth defects and neonatal morbidity caused by teratogen exposure after the embryonic period. / Scheuerle, Angela E.; Aylsworth, Arthur S.

In: Birth Defects Research Part A - Clinical and Molecular Teratology, Vol. 106, No. 11, 01.11.2016, p. 935-939.

Research output: Contribution to journalArticle

@article{63845d0d601f4e24bc0197623a0fcbe9,
title = "Birth defects and neonatal morbidity caused by teratogen exposure after the embryonic period",
abstract = "Background: Pharmaceutical pregnancy exposure registries seek to evaluate temporal associations between drug exposures and adverse outcomes, particularly congenital anomalies. These registries record observed associations that may or may not be causally-related to the exposure. Most major congenital malformations (i.e., structural birth defects) result from abnormal development during embryogenesis. A standardized catalog of defects of concern (colloquially the “BPA Codes”) is used both in public health surveillance programs and pregnancy exposure registries. There are, however, some anomalies that cause significant morbidity and mortality for which isolated second or third trimester exposures may be pathogenically significant. There currently exists no standardized list of defects for which exposure limited to the fetal period may be problematic. Methods: The six-digit-code list was used to determine anomalies that might result from medication exposures limited to the fetal period. Results: Defects with documented first trimester pathogenesis (e.g., anencephaly, heterotaxy) were eliminated from consideration, as were chromosomal and single gene disorders (e.g., trisomy 21, achondroplasia). The remaining defects include the following: (1) those that are known to or could reasonably originate or manifest after the embryonic period (e.g., porencephaly, cataracts); (2) those for which pathogenesis is unclear or variable enough that exposure at any gestational age might be considered relevant (e.g., club foot, microcephaly); and (3) those that include some component of abnormal growth (e.g., hemihyperplasia). “Unspecified” defects (e.g., “abnormality of the leg”) were included by default because there is insufficient information to assume first trimester embryogenesis. Conclusion: The final result is a list of major and minor anomalies in 11 organ system categories that may be caused by teratogen exposure during the fetal period. Birth Defects Research (Part A) 106:935–939, 2016.",
keywords = "congenital anomaly, fetal period, pharmaceutical pregnancy registry, pregnancy, pregnancy exposure registry, second trimester, teratogen, third trimester",
author = "Scheuerle, {Angela E.} and Aylsworth, {Arthur S.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1002/bdra.23555",
language = "English (US)",
volume = "106",
pages = "935--939",
journal = "Teratology",
issn = "1542-0752",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Birth defects and neonatal morbidity caused by teratogen exposure after the embryonic period

AU - Scheuerle, Angela E.

AU - Aylsworth, Arthur S.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background: Pharmaceutical pregnancy exposure registries seek to evaluate temporal associations between drug exposures and adverse outcomes, particularly congenital anomalies. These registries record observed associations that may or may not be causally-related to the exposure. Most major congenital malformations (i.e., structural birth defects) result from abnormal development during embryogenesis. A standardized catalog of defects of concern (colloquially the “BPA Codes”) is used both in public health surveillance programs and pregnancy exposure registries. There are, however, some anomalies that cause significant morbidity and mortality for which isolated second or third trimester exposures may be pathogenically significant. There currently exists no standardized list of defects for which exposure limited to the fetal period may be problematic. Methods: The six-digit-code list was used to determine anomalies that might result from medication exposures limited to the fetal period. Results: Defects with documented first trimester pathogenesis (e.g., anencephaly, heterotaxy) were eliminated from consideration, as were chromosomal and single gene disorders (e.g., trisomy 21, achondroplasia). The remaining defects include the following: (1) those that are known to or could reasonably originate or manifest after the embryonic period (e.g., porencephaly, cataracts); (2) those for which pathogenesis is unclear or variable enough that exposure at any gestational age might be considered relevant (e.g., club foot, microcephaly); and (3) those that include some component of abnormal growth (e.g., hemihyperplasia). “Unspecified” defects (e.g., “abnormality of the leg”) were included by default because there is insufficient information to assume first trimester embryogenesis. Conclusion: The final result is a list of major and minor anomalies in 11 organ system categories that may be caused by teratogen exposure during the fetal period. Birth Defects Research (Part A) 106:935–939, 2016.

AB - Background: Pharmaceutical pregnancy exposure registries seek to evaluate temporal associations between drug exposures and adverse outcomes, particularly congenital anomalies. These registries record observed associations that may or may not be causally-related to the exposure. Most major congenital malformations (i.e., structural birth defects) result from abnormal development during embryogenesis. A standardized catalog of defects of concern (colloquially the “BPA Codes”) is used both in public health surveillance programs and pregnancy exposure registries. There are, however, some anomalies that cause significant morbidity and mortality for which isolated second or third trimester exposures may be pathogenically significant. There currently exists no standardized list of defects for which exposure limited to the fetal period may be problematic. Methods: The six-digit-code list was used to determine anomalies that might result from medication exposures limited to the fetal period. Results: Defects with documented first trimester pathogenesis (e.g., anencephaly, heterotaxy) were eliminated from consideration, as were chromosomal and single gene disorders (e.g., trisomy 21, achondroplasia). The remaining defects include the following: (1) those that are known to or could reasonably originate or manifest after the embryonic period (e.g., porencephaly, cataracts); (2) those for which pathogenesis is unclear or variable enough that exposure at any gestational age might be considered relevant (e.g., club foot, microcephaly); and (3) those that include some component of abnormal growth (e.g., hemihyperplasia). “Unspecified” defects (e.g., “abnormality of the leg”) were included by default because there is insufficient information to assume first trimester embryogenesis. Conclusion: The final result is a list of major and minor anomalies in 11 organ system categories that may be caused by teratogen exposure during the fetal period. Birth Defects Research (Part A) 106:935–939, 2016.

KW - congenital anomaly

KW - fetal period

KW - pharmaceutical pregnancy registry

KW - pregnancy

KW - pregnancy exposure registry

KW - second trimester

KW - teratogen

KW - third trimester

UR - http://www.scopus.com/inward/record.url?scp=84994680329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994680329&partnerID=8YFLogxK

U2 - 10.1002/bdra.23555

DO - 10.1002/bdra.23555

M3 - Article

C2 - 27511745

AN - SCOPUS:84994680329

VL - 106

SP - 935

EP - 939

JO - Teratology

JF - Teratology

SN - 1542-0752

IS - 11

ER -